Compare T-Mobile Us Inc (TMUS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs Tango Therapeutics Inc. — how do they compare? T-Mobile Us Inc trades at $158.2 (market cap $164.91B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: T-Mobile Us Inc is far larger — about 44× Tango Therapeutics Inc.'s market cap, and T-Mobile Us Inc pays a 3.04% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Mobile Us Inc for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| TMUS | TNGX | |
|---|---|---|
Market Cap | $164.91B | $3.75B |
Volume | 5,684,850 | 9,619,106 |
Sector | Media | Health |
52-Week High | $230.06 | $32.90 |
52-Week Low | $148.58 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $281.53B | $2.77B |
Dividend Yield | 3.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T-Mobile US (TMUS) trades at $157.79, up 3.9% with strong recent earnings beats but faces technical bearish signals. The company maintains robust fundamentals with $88.31B revenue (2025), 11.45% net margin, and attractive valuation ratios (P/E 16.08, EV/EBITDA 8.73). Recent developments include a 15% dividend hike and AI-powered 5G network enhancements, though debt levels remain elevated at $84.6B.
TMUS presents a compelling growth story with solid profitability and analyst support (81% buy rating, $221.75 target), but investors must weigh technical weakness against fundamental strength. Key risks include competitive pressures, macroeconomic uncertainty, and the company's substantial debt load in a rising rate environment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
